L7 Informatics, a provider of scientific software solutions for research, development, manufacturing, and quality control operations, has formed a partnership with Cellipont Bioservices, a contract development and manufacturing organization (CDMO) specializing in cell therapy manufacturing. Cellipont will use L7 Informatics’ L7|ESP unified platform and its integrated Manufacturing Execution System (MES) application to digitalize its cell therapy manufacturing recipes, streamline technology transfers, and digitally enable its customers. L7|ESP MES offers advanced capabilities and flexibility to manage early and late-phase clinical to commercial programs with a unified process, data, and knowledge management platform to enable manufacturing, quality, and technology transfer operations end-to-end.

“The decision to deploy L7|ESP reflects our commitment to staying at the forefront of innovation in this dynamic field,” said Mike O’Mara, chief operations officer, Cellipont. “While we chose L7 to take advantage of its MES application, we will also leverage L7 Informatics’ flexible platform to streamline our processes, enhance collaboration, and ultimately deliver even greater value to our clients and the broader scientific community.”

Vasu Rangadass, CEO, L7 Informatics, said, “We are thrilled to collaborate with Cellipont as they deploy L7|ESP. They have built a state-of-the-art facility and assembled a well-experienced technical team to develop and manufacture cell therapies. We designed our platform to empower organizations like Cellipont to create efficiencies and harness the full potential of their operations and data management. We are committed to providing transformative solutions that meet the evolving needs of cell therapy research, development, and manufacturing.”